Table 1. Patient Characteristics at Baseline.
| Characteristic | Patients (N = 24)a |
|---|---|
| Sex | |
| Female | 24 (100) |
| Male | 0 |
| Age, median (range), y | 46 (25-74) |
| ECOG performance status | |
| 0 | 17 (70.8) |
| 1 | 7 (29.2) |
| Clinical situation after neoadjuvant chemotherapy | |
| Incomplete pathologic response after surgery | 21 (87.5) |
| Inflammatory and unresectable | 2 (8.3) |
| Locoregional and unresectable | 1 (4.2) |
| T categoryb | |
| T1 | 4 (16.7) |
| T2 | 14 (58.3) |
| T3 | 4 (16.7) |
| T4 | 2 (8.3) |
| N categoryb | |
| N0 | 13 (54.2) |
| N1 | 10 (41.7) |
| N2 | 1 (4.2) |
| M categoryb | |
| M0 | 24 (100) |
| M1 | 0 |
| Residual disease burdenc | |
| I | 2 (9.5) |
| II | 15 (71.4) |
| III | 4 (19.0) |
| Ki-67, median (range), % | 60 (20-80) |
| Elston-Ellis graded | |
| 2 | 5 (20.8) |
| 3 | 18 (75.0) |
| Not available | 1 (4.2) |
| Homologous recombination deficiency | |
| Yes | 14 (58.3) |
| No | 7 (29.2) |
| Undetermined | 1 (4.2) |
| Not tested | 2 (8.3) |
| BRCA1/2 variant carrier | |
| Yes | 7 (29.2) |
| No | 15 (62.5) |
| Not tested | 2 (8.3) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
a
Data are reported as number (percentage) of patients unless otherwise indicated.
b
According to American Joint Committee on Cancer criteria. N category percentages do not sum to 100% because of rounding.
c
The residual disease burden (residual cancer burden [RCB]) score can only be calculated after surgery.15 Thus, the RCB score was only available for 21 patients who were included in the trial after undergoing surgery. Percentages do not sum to 100% because of rounding.
d
Grades range from 1 to 3, with higher grades indicating poorly differentiated breast cancer and fast-growing cancer.